menu
    • menu

    Company profile for Gyre Therapeutics

    NEW Drugs in Dev: 5
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Gyre Therapeutics, based in San Diego, CA, is a biopharmaceutical company with a primary focus on developing and bringing to market Hydronidone (F351) for treating Metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis. Formerly known as Nonalcoholic Steatohepatitis (NASH), MASH fibrosis is the target condition for Hydronidone, currently under evaluation for the treatment of liver fibrosis in various...
    Gyre Therapeutics, based in San Diego, CA, is a biopharmaceutical company with a primary focus on developing and bringing to market Hydronidone (F351) for treating Metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis. Formerly known as Nonalcoholic Steatohepatitis (NASH), MASH fibrosis is the target condition for Hydronidone, currently under evaluation for the treatment of liver fibrosis in various chronic liver diseases in the United States. The drug is being assessed under an active Investigational New Drug (IND) application.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Gyre TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12770 High Bluff Drive, Suite 150 San Diego, CA 92130
    Telephone
    Telephone
    +1 8585677770
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gyretx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Bio-Europe Spring

    Bio-Europe Spring

    Not Confirmed

    envelop Contact Supplier

    Bio-Europe Spring

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gyre Therapeutics Receives China NMPA Priority Review
    Gyre Therapeutics Receives China NMPA Priority Review

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257004/0/en/Gyre-Therapeutics-Announces-China-s-NMPA-Grants-Priority-Review-to-the-NDA-for-Hydronidone-F351-for-CHB-Induced-Liver-Fibrosis-Treatment.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Gyre Therapeutics: Q4/FY 2025 Financial Results, Business Update
    Gyre Therapeutics: Q4/FY 2025 Financial Results, Business Update

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254390/0/en/Gyre-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    Cullgen Ditches Reverse Merger With Pulmatrix To Go With Gyre
    Cullgen Ditches Reverse Merger With Pulmatrix To Go With Gyre

    02 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cullgen-ditches-reverse-merger-pulmatrix-go-gyre-300m-buyout

    FIERCE BIOTECH
    02 Mar 2026
    Share Share
    Gyre Therapeutics Acquires Cullgen's Targeted Platform & Pipeline
    Gyre Therapeutics Acquires Cullgen's Targeted Platform & Pipeline

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247348/0/en/Gyre-Therapeutics-Enters-into-Agreement-to-Acquire-Cullgen-to-Gain-Targeted-Protein-Degradation-Platform-and-Pipeline.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Gyre Aligns with China's CDE on Hydronidone Review
    Gyre Aligns with China's CDE on Hydronidone Review

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212606/0/en/Gyre-Therapeutics-Announces-Alignment-with-China-s-CDE-on-Conditional-Approval-Pathway-and-Priority-Review-Eligibility-for-Hydronidone-Following-Pre-NDA-Meeting.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Gyre Therapeutics Reports Q3 2025 Financials And Business Update
    Gyre Therapeutics Reports Q3 2025 Financials And Business Update

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183482/0/en/Gyre-Therapeutics-Reports-Third-Quarter-2025-and-Year-to-Date-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search